Drug intelligence / Profile preview

Neuro-Cells

Development stage: Phase 3
Lead developer: Neuroplast
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intrathecal

Overview

Neuro-Cells is an autologous fresh stem cell-containing product developed by Neuroplast. It is designed to treat traumatic spinal cord injury (TSCI) by modulating secondary inflammation, reducing apoptosis (cell death) in the injured spinal cord, decreasing scar tissue formation, and fostering a cell regenerative environment within the damaged spinal cord.

Brand names: Neuro-Cells
Other names: autologous somatic cell therapy

Beyond the preview

Go deeper on Neuro-Cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neuro-Cells.

Explore the full profile